INFLAMMATory disorder programs

ELB353

ELB353 is a phosphodiesterase 4 (PDE4) inhibitor, with therapeutic potential in chronic inflammatory disorders. The primary area of interest is chronic obstructive pulmonary disease (COPD), a disabilitating disorder with major unmet medical need.

Read more

VAP-1, a key inflammation receptor

Vascular Adhesion Protein-1 (VAP-1) is Biotie’s proprietary target and is protected by patents held by the company. VAP-1 has been shown to play a key role in mediating the inflammatory events associated with chronic diseases such as rheumatoid arthritis, psoriasis and diabetes.

Read more

VAP-1 Antibody

Biotie is developing a fully human monoclonal antibody which blocks VAP-1 function thereby allowing the inflammation to resolve.

Read more

----

Updated March, 2010